Etodolac

Specifications

41340-25-4CAS Number

629-689-1EC Number

2-(1,8-diethyl-4,9-dihydro-3H-pyrano[3,4-b]indol-1-yl)acetic acidIUPAC Name

C17H21NO3Chemical Formula

287.35 g/molMolecular Weight

etodolac; 41340-25-4; Etodolic acid; Lodine; Ultradol; Lodine XL; Edolan; Ramodar; Etodolaco; Zedolac; AY-24236; Etodolacum; Tedolan; AY-24,236; AY 24236; Eccoxolac; Flancox; Napilac; Lodin xl; 1,8-Diethyl-1,3,4,9-tetrahydropyrano[3,4-b]indole-1-acetic acid; DTXSID9020615; (rs)-etodolic acid; Pyrano[3,4-b]indole-1-acetic acid, 1,8-diethyl-1,3,4,9-tetrahydro-; Lodine SR; 1,3,4,9-Tetrahydro-1,8-diethylpyrano(3,4-b)indole-1-acetic acid; 1,8-Diethyl-1,3,4,9-tetrahydropyrano(3,4-b)indole-1-acetic acid; NSC-282126; CHEBI:4909; Pyrano(3,4-b)indole-1-acetic acid, 1,8-diethyl-1,3,4,9-tetrahydro-; NIH-9918; NSC282126; DTXCID30615; AY-24-236; (+-)-1,8-Diethyl-1,3,4,9-tetrahydropyrano(3,4-b)indole-1-acetic acid; (1,8-Diethyl-1,3,4,9-tetrahydro-pyrano[3,4-b]indol-1-yl)-acetic acid; 2M36281008; 1,8-diethyl-1,3,4,9-tetrahydropyrano[3,4-b]indol-1-ylacetic acid; Ebretin; Etolyn; 1,8-diethyl-1,3,4,9-tetrahydropyrano(3,4-b)indol-1-ylacetic acid; Etopan xl; EtoGesic Tablets; (1,8-Diethyl-1,3,4,9-tetrahydro-pyrano(3,4-b)indol-1-yl)-acetic acid; Etodolac ER; RefChem:55167; AY 24,236; M01AB08; Etogesic Sterile Injectable Solution; 2-((1RS)-1,8-Diethyl-1,3,4,9-tetrahydropyrano(3,4-b)indol-1-yl)acetic acid; rac-Etodolac; 2-(1,8-diethyl-1,3,4,9-tetrahydropyrano[3,4-b]indol-1-yl)acetic acid; 2-(1,8-diethyl-4,9-dihydro-3H-pyrano[3,4-b]indol-1-yl)acetic acid; MFCD00133313; CHEMBL622; (+/-)-ETODOLAC; MLS000028474; 2-{1,8-diethyl-1H,3H,4H,9H-pyrano[3,4-b]indol-1-yl}acetic acid; (1,8-Diethyl-1,3,4,9-tetrahydropyrano[3,4-b]indol-1-yl)acetic acid; SMR000058443; Etodolacum [INN-Latin]; Etodolaco [INN-Spanish]; Hypen; (+/-)-1,8-diethyl-1,3,4,9-tetrahydropyrano(3,4-b)indole-1-acetic acid; CCRIS 3923; SR-01000000100; NSC 282126; Osteluc; etodolac o; Etodolie acid; rac Etodolac; 2-(1,8-Diethyl-1H,3H,4H,9H-pyrano[3,4-b]indol-1-yl)acetic acid; Etodlic Acid; Etodolac CRS; Etodolac [USAN:USP:INN:BAN]; RAK-591; NCGC00016849-01; Prestwick_209; CAS-41340-25-4; Etodolac (Standard); Lodine (TN); UNII-2M36281008; Spectrum_001244; ETODOLAC [USAN]; ETODOLAC [INN]; ETODOLAC [JAN]; ETODOLAC [MI]; Etodolac impurity mixture; ETODOLAC [VANDF]; Opera_ID_1774; Prestwick0_000231; Prestwick1_000231; Prestwick2_000231; Prestwick3_000231; Spectrum2_001387; Spectrum3_001429; Spectrum4_000410; Spectrum5_001347; ETODOLAC [MART.]; Epitope ID:613427; ETODOLAC [USP-RS]; ETODOLAC [WHO-DD]; (RS)-2-(1,8-Diethyl-4,9-dihydro-3H-pyrano[3,4-b]indol-1-yl)acetic acid; SCHEMBL3903; Lopac0_000479; BSPBio_000301; BSPBio_003138; KBioGR_000680; KBioSS_001724; Etodolac - Bio-X trade mark; MLS001077315; MLS006011566; DivK1c_000147; ETODOLAC [GREEN BOOK]; SPECTRUM1501005; Etodolac (JP19/USP/INN); SPBio_001374; SPBio_002222; ETODOLAC [ORANGE BOOK]; BPBio1_000333; GTPL7185; orb1225093; orb1310080; orb3025562; ETODOLAC [EP MONOGRAPH]; ETODOLAC [USP MONOGRAPH]; SCHEMBL29385172; HMS500H09; KBio1_000147; KBio2_001724; KBio2_004292; KBio2_006860; KBio3_002358; MSK8008; (R)-2-(1,8-diethyl-1,3,4,9-tetrahydropyrano[3,4-b]indol-1-yl)acetic acid; NINDS_000147; HMS1568P03; HMS1921B09; HMS2092O20; HMS2095P03; HMS2231D04; HMS3259P10; HMS3261O20; HMS3374G09; HMS3712P03; HMS5079D11; Pharmakon1600-01501005; BBC19746; Tox21_110644; Tox21_202218; Tox21_500479; 1,8-diethyl-1,3,4,9-tetrahydro-pyrano[3,4-b]indole-1-acetic acid; BDBM50016799; CCG-39005; EBC-11162; Etodolac for peak identification CRS; HY-76251R; MSK8008-100A; NSC757821; Pyrano(3,4-b)indole-1-acetic acid, 1,3,4,9-tetrahydro-1,8-diethyl-; s1328; AKOS015838610; MSK8008-1000A; Pyrano(3,4-b)indole-1-acetic acid, 1,8-diethyl-1,3,4,9-tetrahydro-(+-)-; Tox21_110644_1; AC-4231; CS-0832; DB00749; FR27516; LP00479; NC00718; NSC-757821; SDCCGSBI-0050463.P004; IDI1_000147; NCGC00015399-03; NCGC00015399-04; NCGC00015399-05; NCGC00015399-06; NCGC00015399-07; NCGC00015399-08; NCGC00015399-09; NCGC00015399-11; NCGC00015399-12; NCGC00015399-13; NCGC00015399-15; NCGC00015399-16; NCGC00015399-24; NCGC00015399-26; NCGC00015399-27; NCGC00089769-02; NCGC00089769-03; NCGC00089769-04; NCGC00089769-05; NCGC00089769-06; NCGC00089769-07; NCGC00259767-01; NCGC00261164-01; BR164431; HY-76251; SY057989; SBI-0050463.P003; AB00052194; E0858; E7556; Etodolac Solution in Acetonitrile, 100ug/mL; EU-0100479; NS00010209; Etodolac Solution in Acetonitrile, 1000ug/mL; C06991; D00315; E 0516; EN300-119494; Pyrano[3, 1,8-diethyl-1,3,4,9-tetrahydro-; AB00052194_17; F358075; Q2465218; SR-01000000100-2; SR-01000000100-4; SR-01000000100-7; BRD-A74667430-001-05-3; BRD-A74667430-001-15-2; BRD-A74667430-001-23-6; 1,3,4,9-tetrahydropyrano[3,4-b]indole-1-acetic acid; Etodolac, European Pharmacopoeia (EP) Reference Standard; F2173-0681; Z1521549186; Etodolac, United States Pharmacopeia (USP) Reference Standard; 1,8-Diethyl-1,3,4,9-tetrahydropyranol[3,4-b]indole-1-acetic acid; 1,8-DIETHYL-1,3,4,9-TETRAHYDROPYRANO(3,4-B)INDOL-1-ACETIC ACID; Pyrano(3,4,b)indole-1-acetic acid, 1,3,4,9-tetrahydro-1,8-diethyl-; Etodolac for peak identification, European Pharmacopoeia (EP) Reference Standard; PYRANO(3,4-B)INDOLE-1-ACETIC ACID, 1,8-DIETHYL-1,3,4,9-TETRAHYDRO-(+/-)-; Etodolac Micronized; Edotolac; Étodolique acideSynonyms